We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002052
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Condition Intervention
HIV Infections Salmonella Infections Drug: Ceftriaxone sodium Drug: Ampicillin sodium Drug: Amoxicillin trihydrate

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Prior Medication:

Excluded within 48 hours of study entry:

  • Treatment with an antibiotic active in vitro against Salmonella.

HIV infection, AIDS, or AIDS related complex (ARC).

  • Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002052


Locations
United States, California
Los Angeles County - USC Med Ctr
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
  More Information

ClinicalTrials.gov Identifier: NCT00002052     History of Changes
Other Study ID Numbers: 019A
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: August 1989

Keywords provided by NIH AIDS Clinical Trials Information Service:
Salmonella Infections
AIDS-Related Opportunistic Infections
Acquired Immunodeficiency Syndrome
Amoxicillin
Ceftriaxone

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Salmonella Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Amoxicillin
Ceftriaxone
Ampicillin
Anti-Bacterial Agents
Anti-Infective Agents